Business Context and Reporting Period
This Form 8-K Current Report was filed by Contineum Therapeutics, Inc. (Nasdaq: CTNM) on June 21, 2024. The report discloses corporate governance changes, specifically the appointment of a new director and committee chair effective June 24, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
- Board Appointment: Sarah Boyce was appointed as a member of the Board of Directors, effective June 24, 2024.
- Committee Leadership: Ms. Boyce was appointed as Chair of the Nominating and Corporate Governance Committee, replacing Lori Lyons-Williams, who remains a committee member.
- Director Class: Ms. Boyce serves as a Class I director with a term expiring at the 2025 annual meeting.
Guidance, Outlook, and Compensation
The filing contains no financial guidance, outlook, or management commentary regarding business operations. Regarding compensation, Ms. Boyce will receive cash and equity under the existing Non-Employee Director Compensation Program, including an initial grant of an option to purchase 29,500 shares of Class A common stock. She has also entered into a standard indemnification agreement.
Investor Verification Checklist
- Verify the effective date of Sarah Boyce's board appointment (June 24, 2024).
- Confirm the specific equity grant size (29,500 share options) and its terms under the Non-Employee Director Compensation Program.
- Review Ms. Boyce's background, including her current role as CEO of Avidity Biosciences, to assess potential conflicts of interest or strategic alignment.
- Check subsequent filings for any changes to the composition of the Nominating and Corporate Governance Committee.